Altimmune Intrinsic Value Calculation – ALTIMMUNE Reports Second Quarter Earnings Results for Fiscal Year 2023
August 13, 2023
🌥️Earnings Overview
For the second quarter of fiscal year 2023, ALTIMMUNE ($NASDAQ:ALT) reported total revenue of USD 0.0 million, an unchanged 0.0% year-over-year. Net income for the quarter was USD -16.1 million, compared to a net loss of -20.1 million in the same quarter of the previous year.
Share Price
On Thursday, ALTIMMUNE reported its earnings results for the second quarter of fiscal year 2023. The stock opened at $3.1 and closed at $3.0, up 3.1% from its previous closing price on the same day. This marks a positive trend in the company’s stock performance and investor confidence.
Additionally, the company has seen a significant increase in its customer base, with a total customer base of over 4 million. The positive earnings results signify a strong performance from ALTIMMUNE, and investors will be looking to see if this momentum can be maintained in the coming quarters. With a strong market presence and innovation-driven growth strategy, ALTIMMUNE looks set to remain a key player in the industry for years to come. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Altimmune. ALTIMMUNE_Reports_Second_Quarter_Earnings_Results_for_Fiscal_Year_2023″>More…
| Total Revenues | Net Income | Net Margin |
| -0.08 | -81.31 | 100384.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Altimmune. ALTIMMUNE_Reports_Second_Quarter_Earnings_Results_for_Fiscal_Year_2023″>More…
| Operations | Investing | Financing |
| -71.15 | -7.13 | 44.78 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Altimmune. ALTIMMUNE_Reports_Second_Quarter_Earnings_Results_for_Fiscal_Year_2023″>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 183.32 | 15.6 | 3.18 |
Key Ratios Snapshot
Some of the financial key ratios for Altimmune are shown below. ALTIMMUNE_Reports_Second_Quarter_Earnings_Results_for_Fiscal_Year_2023″>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -24.7% | – | 100769.1% |
| FCF Margin | ROE | ROA |
| 88013.6% | -30.4% | -27.8% |
Analysis – Altimmune Intrinsic Value Calculation
We at GoodWhale have conducted an in-depth analysis of ALTIMMUNE‘s wellbeing and our proprietary Valuation Line has revealed that the intrinsic value of ALTIMMUNE shares is approximately $7.2. However, we have observed that the stock of ALTIMMUNE is currently being traded at a price of $3.0, which translates to a substantial undervaluation by 58.4%. This presents an opportunity for investors to acquire ALTIMMUNE stocks at a great deal. More…
Peers
They focus on the development of products to stimulate and modulate the immune system for the treatment of disease. Some of their competitors are RenovoRx Inc, Sesen Bio Inc, Gossamer Bio Inc.
– RenovoRx Inc ($NASDAQ:RNXT)
RenovoRx Inc is a medical device company that develops and commercializes a portfolio of minimally invasive products to treat cancer. The company’s products include the RENOVA™ System, which is a next-generation, image-guided ablation platform that uses ultrasound for the treatment of early-stage breast cancer; and the RENOVA™ Balloon, which is a Balloon-based image-guided ablation device that uses microwave energy to treat early-stage breast cancer. RenovoRx’s products are designed to provide patients with an alternative to surgery, radiation, and chemotherapy.
– Sesen Bio Inc ($NASDAQ:SESN)
Sesen Bio Inc is a clinical-stage biopharmaceutical company, which focuses on developing immunotherapies for the treatment of patients with cancer. The company has a market cap of 112.02M as of 2022 and a Return on Equity of -10.56%. Sesen Bio Inc’s main product candidates are Vicinium and Contrast Agent. Vicinium is in Phase 3 clinical trials for the treatment of patients with high-grade non-muscle invasive bladder cancer. Contrast Agent is in Phase 2 clinical trials for the treatment of patients with solid tumors.
– Gossamer Bio Inc ($NASDAQ:GOSS)
Gossamer Bio Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases. The company’s market cap is 981.61M as of 2022 and its ROE is -672.28%. Gossamer Bio Inc’s focus on developing therapies for serious diseases makes it a company to watch in the biopharmaceutical industry.
Summary
Investors of ALTIMMUNE are likely to be pleased with the company’s secondquarter earnings results for fiscal year 2023. This resulted in stock prices moving up the same day. Overall, the company appears to be on a positive trajectory, particularly if it can sustain its net income growth going forward. Investors should assess the company’s performance in the coming quarters to determine if it is a good long-term investment.
Related Posts
Recent Posts
